Yes, please elaborate...

Yes, the SP hit 2.98 today, but it did/will not close @2.98, so the forehead star will not remain until WISH sees a close @2.98 or lower.

Well, 2.98 has been hit and someone gets a gold star affixed to his forehead.

Just cannot trust Steiner.

Lie to the investors and suffer the consequences...

Did Cramer mention VERU?

Why else would the SP go down on good news?

Steiner selling into the news?

Interesting thoughts from another mind

cutenurse
11m
$DARE


So everyone knows and if someone says it's not true they just don't know what they are talking about..(SHORTS and Speculators) This paragraph is right from the Companys filing and is Gospel..

Dare has been in negotiations since before September and they intend to announce there commercialization before the end of the year.

Anyone that tells you the Halt killed the pps doesn't know what they are talking about.

1. The company had to ask for the Halt. They don't just Halt the stock for 6 hr because they want to kill the share price. That's nonsense.

2. There may be more than One Company trying to get a licensing agreement.

3. The Partner may have asked Sabrina for a 10% stake in DARE as part of the deal.

4.The Partner may have offered Sabrina a buyout offer and it took a couple hours for the board to decline the offer causing the delay.

All we know is something was put on the table after the approval that caused Sabrina to keep the stock Halted.

We are delivering innovation by daring to be different®

https://ir.darebioscience.com/static-files/ed3576c1-9d81-48b5-8300-1eef146d5ad7

For once, I must agree with you!

BUT

she would never take it.

$Dare Will Rocket Higher, As "Partner Talks Percolate As FDA Clears Daré Gel For BV." Strong Buy!

https://seekingalpha.com/instablog/2694641-biotechlab/5673583-dare-will-rocket-higher-partner-talks-percolate-fda-clears-dare-gel-for-bv-strong-buy

Summary
Partner talks percolate as FDA clears Daré gel for BV.
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis.
"Strategic partnering discussions ongoing; Conference call will be scheduled once a definitive partnership agreement for commercialization of XACIATO in the U.S. is finalized and executed; U.S. commercial launch expected 2022."
Now is the time to buy DARE!
Daré Bioscience Inc.’s investors will have to wait a while for details regarding a commercialization partnership centered on Xaciato (2% clindamycin phosphate gel, formerly known as DARE-BV1) as a single-dose treatment of bacterial vaginosis in females 12 years of age and older. Approved Dec. 7, Xaciato is expected to launch next year.

https://www.bioworld.com/articles/514071-partner-talks-percolate-as-fda-clears-daré-gel-for-bv?v=preview

Keeping it interesting as we wait... WISHing...

Please, Cramer, no more thoughts about VERU!

WORDS FROM SOMEONE MUCH SMARTER THAN I

For those of you new to DARE, wondering when to sell (or buy) this stock.

First, Dare is a phenomenal, one of a kind company, not only in the biotech industry, but when compared to other tickers from any field or industry. Within its own industry, biotech clinical stage pharmas (well, not any more since they now move towards commercialization as well), DARE is a rare find, an exceptional company in several ways. Here are a few things you should know about it:

1. Vision: this is a company that has a very very clear identity, knows exactly what it is aiming for, and does NOT get distracted. This is very uncommon in biotech pharmas. As companies develop drugs, they "stumble" upon new findings that open doors to new ideas for drugs, development, etc. Covid is the best, but not the only, example. SOOOOO many companies decided to take a shot at finding a cure/vaccine/testing device for Covid, moving their focus away from their original pipeline. Not DARE, they never flinched. Stayed focused on their goals all the way through.

The vision of the company is practical, smart and geared to achieving rapid financial success. This is also a rare find in biotech pharmas. The company first thought about how to make money, then about how to develop the products, not the other way around.

What do they do differently? They do NOT develop new drugs. Instead, they take EXISTING drugs and find use for them in their specific niche: women's health.

That is a big advantage, because it allows them to receive approvals in a much certain and easier path, since they are not seeking to approve a totally new drug, simply a drug already approved, for a different use.

This way, staying focused on women's health only, bringing a team together that specialized in that specific niche and then finding new ways to use drugs that already went through an approval process, DARE has been able to push its pipeline extremely fast all the way to approval.

2. Leadership: show me another CEO with a proven track record of constant success earning less than 500K per year. The woman leading Dare is the ultimate professional. Doesn't look for any free meals, she is going to earn those billions with the results she achieves, not by abusing shareholders money. Excellent speaker, excellent deal-maker, she is first and foremost a businesswoman. So many companies in the sector are run by scientists who, smart as they might be, are terrible CEO's. Here we have the opposite, a talented, humble, sharp woman that knows her business and lets scientist take care of the lab while she takes excellent care of our money.

3. Pipeline: DARE just approved its first product, but ALL the products in the pipeline are very very promising. There are good news scheduled for this month yet, let alone Q1 of 2022. Just to give an example everyone can understand: they are using the same substance that Viagra is made of, to develop a Viagra for women. Again, not trying to make something new, just take something that already exists (viagra) and give it a use for women. And yes, this is a huge thing. Just like men, women are unable to "feel" pleasure at a certain age, etc. It's in fact the same issue that men face, just without the embarrassment. But it is a huge market for a product that women simply don't have today. And that, is just one of the products DARE is developing.

4. Partnerships: Take all the above, mix them together, and what do you get? A company that knows how to, and is not afraid of, making profitable partnerships. That is why they are already partnered with the Bill Gates Foundation, Bayer, and the Kennedy-Shriver Center. Their CEO doesn't make the same mistakes many small new pharmaceutical companied do, she gets to work and makes fast, meaningful partnerships to sustain the company and allow its rapid growth.

5. So, when should you sell? Or buy? Simple: buy now. This stock is extremely undervalued even if it jumps to 5 or 6. Getting to double figures next year is a very strong probability. And right now it's at about 3. The stock has a history of moderate price increase following big news. Contrary to most stock that have a sudden big jump, DARE in the past has moved moderately after a big announcement, only to gain traction in the following days.
And don't sell. DARE will announce a commercialization partnership for its new drug this month. And it is set to announce results for one of its clinical trials this month. The price will continue to grow into 2022. Hold and be amply rewarded.

I'm not a financial advisor. I have been holding a long position in DARE.

*CHOMP* *CHOMP*

some tasty morsels @1.83 and back up to 1.89

If they are dumping all now... better it be now than during the open market hours.

We should be back up tomorrow (with luck).

Some deals happening right now in the aftermarket

More excitement needs to be created.

This board has been quiet for a while, only to awaken recently with the FDA approval.

There have got to be many opinions as to the forword movement of the company and it's products, prospective partners, and ongoing trials.

Rebound to ?

Taking valid goosebump PT's

I don't think any of that is necessary.
The short percentage is low.
The company is preparing for a bombshell release (Think about the reason for the halt yesterday).
Get ready for goosebumps!

I stole a MEGA-BUNCH @1.91

The halt yesterday was interesting...
too interesting to pass up...

Volume Required=250-350MM

UH HUH!

I totally agree.

This is a no-brainer.

HMMMMMMMMMMMM Wafflers or Institutions

I just don't know who to follow...



*GRINZ*

Amusing quotes:

There certainly seems to be a run on WISH WAFFLES!

One week ago...

Cherry picking posts.

How about the wrong prognostications?

Waffle Time...

Not going to be drawn into a battle of which side the waffle is being toasted at this time; just enjoying the show

as always...

with Malcolm

The funniest thing I have heard all year was

MMMMMMMMMMMMMMMMM

YUM YUM

WISH WAFFLES!!

ContextLogic Inc. (NASDAQ:WISH) Receives $14.32 Consensus Price Target from Brokerages

DEC 5, 2021

https://www.tickerreport.com/banking-finance/8184805/contextlogic-inc-nasdaqwish-receives-14-32-consensus-price-target-from-brokerages.html

ContextLogic: “We actually think this company is a decent company, and they’re throwing it away. I mean look, you buy it at $3, can it go to zero? I guess so, but it’s a good [speculative play].”

https://www.cnbc.com/2021/12/03/cramers-lightning-round-i-prefer-pfizers-stock-over-novavax-.html

It seems to have something to do with the price of waffles; which may be going up today...

WISH
Shares Outstanding 577M
Implied Shares Outstanding 643M
Float 439.64M
% Held by Insiders 4.50%
% Held by Institutions 51.28%
Shares Short (Nov 15, 2021) 59.48M
Short Ratio (Nov 15, 2021) 1.61
Short % of Float (Nov 15, 2021) 26.42%

Institutions and shorts control WISH

Does one listen to a talking waffle

or

sit tight like the institutions and let this play out?

I wonder if Jack Dorsey is contemplating a new CEO position in a certain e-commerce company...

Your quote was:

Nothing new, everyone still waiting outcome.

Two days ago read we read: